肺癌靶向维持治疗病例分享__培训课件.pptVIP

主要终点PFS*: 所有患者 (ITT) PFS probability 1.0 0.8 0.6 0.4 0.2 0 0 8 16 24 32 40 48 56 64 72 80 88 96 Time (weeks) HR=0.71 (0.62–0.82) Log-rank p0.0001 Erlotinib (n=437) Placebo (n=447) *PFS从随机化开始接受维持治疗计算；每6周评估一次 Cappuzzo et al, Lancet Oncol 2010, 11(6):521-9 PFS probability 1.0 0.8 0.6 0.4 0.2 0 HR=0.71 (0.62–0.82) Log-rank p0.0001 Erlotinib Placebo PFS at 12 wks (%) 53 40 PFS at 24 wks (%) 31 17 mPFS(weeks) 12.3 11.1 OS: 所有患者(ITT) Cappuzzo et al, Lancet Oncol 2010, 11(6):521-9 厄洛替尼维持治疗突变人群获益更多 Log-rank p0.0001 HR=0.10 (0.04–0.25) 1.0 0.8 0.6 0.4 0.2 0 时间 (周) 厄洛替尼 (n=22) 安慰剂 (n=27) Log-rank p=0.